Next 10 |
home / stock / bgne / bgne articles
U.S. stocks were higher, with the Nasdaq Composite gaining over 200 points on Tuesday. Shares of HealthStream, Inc. (NASDAQ:HSTM) rose sharply duri...
U.S. stock futures were higher this morning, with the Dow futures gaining by around 0.1% on Friday. Shares of Lululemon Athletica Inc. (NASDAQ: L...
On Thursday, the FDA approved BeiGene Ltd’s (NASDAQ:BGNE) approved Tevimbra (tislelizumab-jsgr) as monotherapy for adult patients w...
U.S. stock futures were mixed this morning, with the Nasdaq futures falling by around 20 points on Wednesday. Shares of The Beauty Health Company ...
BeiGene (NASDAQ: BGNE) is expected to report its fourth-quarter 2023 results soon. BeiGene currently markets three internally discovered oncology p...
Amid efforts to expand the Hang Seng Index, Hong Kong’s stock benchmark, Prada (OTC:PRDSY), XPeng (NYSE:XPEV), and BeiGene (NASDAQ:BGNE) are ...
JP Morgan assumed coverage on BeiGene Ltd (NASDAQ:BGNE), highlighting the potential upside and emphasizing that the recent pullback ...
Key Takeaways: Junshi Bio will receive milestone payments and 20% of sales of its PD-1 drug Toripalimab in the U.S., following the drug’s re...
Gainers Carbon Revolution Public Limited (NASDAQ: CREV) shares jumped 396.2% to $145.49 after gaining 100% on Friday. The company’s stock b...
News, Short Squeeze, Breakout and More Instantly...
BeiGene Ltd. Company Name:
BGNE Stock Symbol:
NASDAQ Market:
Multiple presentations to showcase the efficacy and safety of BRUKINSA ® across a range of B-cell malignancies Company to present three-year data from RATIONALE-306 study of TEVIMBRA ® in advanced or metastatic esophageal squamous cell carcinoma (ESCC) Be...
U.S. stocks were higher, with the Nasdaq Composite gaining over 200 points on Tuesday. Shares of HealthStream, Inc. (NASDAQ:HSTM) rose sharply duri...
Comprehensive development program, including three Phase 3 clinical trials, demonstrated benefit of tislelizumab for patients with treatment-naïve and relapsed NSCLC Decision represents tislelizumab’s second approval in the region BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 0...